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Venous thromboembolism (VTE) is a common health problem for today’s society, and consider-
ing the role that it plays in surgical patients (general surgery, gynecology, and orthopedics), new
advances in our understanding of the procedures and trauma characteristics are relevant and
necessary. The most important and recently published guidelines concerning this problem
have been taken into consideration, leading to articulate investigations and data evaluation.
This project has proposed a data-survey framework available as a questionnaire in order to in-
vestigate application of the guidelines for VTE throughout the national territory. Of the total 714
Italian centers, a random sample of 214 were contacted and asked to take part in this study; of
these, 146 replied (20.4% of total and 68.2% of the sample): 48 departments of general surgery,
46 departments of gynecology, and 52 departments of orthopedics. About 70% of the centers
has appropriate information about surgery as a risk factor for VTE. The answers have provided
evidence of an adequate knowledge of the instrumental and laboratory diagnostic pathways,
useful to conﬁrm the diagnosis of TE (80%). Data waiting compared with morbidity and mortality
rates related to deep vein thrombosis and pulmonary embolism showed an increase of mortality
associated with the diagnostic data timing of supply, with an exponential trend linked to the data
acquisition delay. Both risk stratiﬁcation and adequate application of prophylaxis together with
treatment devices represent a real tool to control morbidity and mortality for VTE. Moreover,
diagnostic data waiting signiﬁcantly inﬂuences adequate prophylaxis. In Italy, only 40% of the
centers are ready to provide diagnostic data within 12 hr.INTRODUCTION
The clinical impact and incidence of venous throm-
boembolism (VTE) have led to a number of leading
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Published online: May 8, 2008scientific societies requesting an accurate definition
of specific guidelines . The guidelines formulated by
the American Society for Chest Physicians (ASCP)1
are routinely used for the stratification of risk and
definition of procedures for prophylaxis and
treatment.
According to such guidelines, over three-fourths
of pulmonary embolism (PE) events occur in medi-
cal patients.2 However, because of the variety of risk
factors in these patients and their individual health
problems (e.g., comorbidities, therapies),3 the
guidelines formulated for these cases are scarcely
applied. The type of procedure as well as trauma
are crucial for VTE in surgical patients (general
surgery, gynecology, and orthopedics). Therefore,
predictive algorithms that should help to identify
high-risk subjects (i.e., those who require intensive
prophylaxis) have been defined.2,4 Appropriate use
of the guidelines is thus an opportunity to decrease319
320 de Franciscis et al. Annals of Vascular Surgerymortality and morbidity rates in this setting.2,5,6 We
have considered that, in addition to appropriate
knowledge of the issue, the availability of specific
technical resources in each health-care structure
may affect dramatically the way guidelines are ap-
plied. We have evaluated the level of knowledge
of VTE guidelines as well as the quantitative and
qualitative information about diagnosis, prophy-
laxis, and treatment of a large number of Italian
health departments that normally cope with pa-
tients at high risk of developing deep vein thrombo-
sis (DVT) and PE.
Although studies based on questionnaires are
generally considered not very rigorous and some-
what approximate, the significant amount of data
collected in this work could stimulate further studies
and strategies to implement guidelines about VTE in
surgical settings.
MATERIALS AND METHODS
Of the total 714 public and private health-care facil-
ities identified by each Health Regional Government
Office and web search results, a random sample of
214 were contacted and asked to take part in the
study. The self-administered questionnaire was
mailed to selected participants and particularly to
physicians who headed the general surgery, gyne-
cology, and orthopedics wards in the centers who
were responsible for answering the questionnaire,
with an accompanying cover letter providing details
on the purpose of the study and a reply-paid, ad-
dressed envelope. To keep track of who responded
and to identify those who required follow-up, each
returned envelope was individually coded with an
identification number. To encourage participation
of those who did not respond to the initial mailed
questionnaire, in order to increase the response
rate, telephone calls and two additional complete
mailings, with another copy of the questionnaire
and of the envelope, were sent to nonrespondents.
The standard form involved a certain number of
questions (Fig. 1). In order to achieve better reliabil-
ity of the collected data and to verify the quality of
the practical approach carried out in each center,
a series of filter questions were employed, with em-
phasis on laboratory and instrumental diagnostic
devices and facilities for treatment, together with
questions related to general information (i.e., not
exclusively related to VTE). Five university centers
(local units) supervised the forwarding and data
collection.
Validation of the questionnaire to reveal major
difficulties and weaknesses was performed througha pilot study, surveying a convenience sample of
20 surgeons, gynecologists, and orthopedists; and
on the basis of the results of the pretesting, modifi-
cations were made to improve the validity of
responses.
RESULTS
Replies were received from 146 centers (20.4% of
total and 68.2% of the sample): 48 departments of
general surgery, 46 departments of gynecology,
and 52 departments of orthopedics.
Health-care centers were used by 12,391,240
individuals (20.4% of the Italian population).
In order to make the statistical data analysis more
uniform, stratification among centers in north
(25,600,000 inhabitants), central (10,900,000 in-
habitants), and south (20,000,000 inhabitants) Italy
was chosen.
 Indications about DVTePE prophylaxis (knowledge of
the risk factors): About 70% of the centers pos-
sessed some appropriate information about sur-
gery as a risk factor for VTE. Of this 70%, only
• INDICATIONS FOR DVT – PE PROPHYLAXIS (Knowledge of Risk
Factors)
When and why do you use prophylaxis treatment?
• DVT – PE clinical indicators of suspect (Knowledge of Main Signs and
Symptoms)
Which is the relevant clinical information for DVT – PE suspect?
• Clinical investigations in suspected DVT – PE (Knowledge of Diagnostic
algorithms)
Which clinical investigations do you consider as important for DVT – PE suspect?
• Availability of diagnostic resources in each clinical department
Which are the  available diagnostic facilities in your department?
• Elapsed time to collect relevant information for diagnosis (Diagnostic Data
Waiting from request to execution of the instrumental / laboratory examination
when VTE is suspected)
 How much is the elapsed time between admission and diagnosis that you
usually record ? (instrumental/laboratory device)
• Morbidity and mortality in DVT – PE: current and retrospective (Last 3 years)
Which was the morbidity and mortality in patients with confirmed DVT and/or
PE during the last 3 years?
• Prophylaxis
What kind of prophylaxis do you use?
• Treatment (before and after surgery)
What kind of drugs do you use before and after surgery?
Fig. 1. The questionnaire.
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related to surgery (Table I).
 Clinical indicators of suspect DVTePE (knowledge of
main signs and symptoms): About 80% of the cen-
ters reported pain and edema as signs of VTE; the
same percentage of centers mentioned dyspnea
and chest pain as symptoms of PE. Other signs
and symptoms were underestimated (Table II).
 Procedural investigations in use for suspect DVTePE
(knowledge of the diagnostic algorithms): The diag-
nostic procedures to consider in case of suspected
DVT are correctly followed by about 80% of the
centers, while in case of suspected PE (similar to
the choice between Computed Tomography An-
giography [angio-TC] and Perfusional Scintigra-
phy [Perf-Scint]) the percentage rises to 90%.
Thus, the data suggest that more attention is
paid to suspected PE rather than DVT (Table III).
 Availability of diagnostic resources in clinical depart-
ments: About 80% of the health care facilities
employ diagnostic resources necessary to confirm
DVTePE. High-cost investigations (magnetic res-
onance angiography [angio-MR] 45-61%, Scint
radiolabeled Fibr 25%) are less common than
the essential diagnostic devices (90%) (Table IV).
 Diagnostic data waiting: Only 40% of the centers
receive confirmation of the clinical suspicion
within 12 hr; in some centers more than 48 hr
is necessary in order to get this important infor-
mation. Generally, 24 hr is requested for confir-
mation (Table V). There is a delay from the
request to the execution when VTE is presumed
(the same for DVT and PE).
 Annual and triennial mortality for DVTePE (number
of cases per 100,000 inhabitants): The recruited cen-
ters replied to specific questions that asked for
data related to mortality about patients with
a certain diagnosis or post-mortem diagnosis (Ta-
ble VI). It is interesting to note that the total mor-
tality for DVT, as indicated by some physicians
who answered the form, is probably due to PE
events not diagnosed in patients with DVT.
 Prophylaxis: About 90% of the centers employ
low-molecular weight heparin (LMWH) or opiate
analgesic (oral anticoagulant [OA]) for prophy-
laxis; physical devices are used in 40% of cases
(Table VII). No association is evident between
risk categories and type of prophylaxis employed.
Medical Treatment before and after
Surgery
Data analyses have shown that 70% of centers
involved in this study usually use LMWH before
surgery and 80% after surgery (Table VIII). OAtreatment is seldom used (0/0.93%). This attitude
is based on the need to choose drugs with the best
risk/benefit (protection/bleeding) ratio in prevent-
ing VTE.
Data concerning diagnostic data waiting and
morbidity/mortality were further analyzed through
stratification of the information divided according to
specific areas (north, center, and south) (Table IX).
There was a sufficient distribution of laboratory
and instrumental diagnostic resources combined
with an incongruous distribution of data waiting:
only 40% of the centers were able to supply diag-
nostic data within 12 hr.
Data waiting were compared with morbidity and
mortality rates related to DVTePE (Table X, Figs. 2-
4). Comparison between data waiting and mortality
showed an increase of mortality in someway associ-
ated to the diagnostic data timing of supply, with an
Table I. Knowledge of the risk factors of TE
Risk factors %
Immobilization 40.3
Major surgical procedures 73.0
Traumas 32.6
Neoplasias 34.6
Previous TE 40.3
Trombophilia 23.6
Obesity 32.6
Age >60 years 48.0
Venous disease 44.2
Other 31.7
Table II. Knowledge of the main signs and
symptoms of DVT and PE
Main signs and symptoms %
DVT
Pain 89.3
Edema 76.3
Fever 24.4
Cutaneous alterations 28.2
Functional alterations 20.6
Homans maneuvre-positive 19.8
Venous reticula 14.5
Other 26.7
PE
Dyspnea 92.5
Thoracic pain 70.1
Cough 27.6
Tachypnea 50.7
Anxiety 19.4
Hemoptysis 26.8
Sweating 19.4
Other 46.2
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delay.
Some data about mortality for DVT have sur-
faced, but they are of uncertain meaning.
Morbidity and Mortality by Type of
Clinical Center (Number of Cases per
100,000 Inhabitants)
Data related to mortality and morbidity of TE linked
to the specialty of the clinical departments where
patients are treated were taken into consideration.
Considering the collected information, an incongru-
ity between data related to morbidity and mortality
has emerged from the replies (Table XI, Figs. 5 and
6). Regarding the questionnaire, all the centers
were asked to reply accurately to the specific re-
quested information but only in case of confirmed
morbidity and mortality.
DISCUSSION
For the last 10years, detailed andexact guidelines for
diagnosis, prophylaxis, and therapy for VTE have
been circulating within the scientific community,
becoming the gold standard for up-to-date practice.
There is no study available about the application of
these guidelines for VTE across a national territory
or results from evaluation of experienced practices.
We received replies from 146 public and private
clinical centers (68.20% of the transmitted ques-
tionnaires), serving 12,391,240 inhabitants. Data
collected from five university research units, each
Table III. Knowledge of the diagnostic
algorithms
Kind of device %
Echo color Doppler 85.8
Echo Doppler 71.7
Doppler 44.9
Phlebography 21.2
Marked fibrinogen vein scintigraphy 29.5
D-dimer evaluation 83.2
Hemocoagulation evaluation 81.6
Homocysteine evaluation 36.2
Thoracic radiography 91.0
Pulmonary spiral CT 69.7
Perfusional scintigraphy 69.5
Ventilatory scintigraphy 38.8
D-dimer evaluation 93.8
Hemocoagulation evaluation 91.0
Lactate dehydrogenase evaluation 83.9
Creatine phosphokinase evaluation 79.7
Alanine aminotransferase evaluation 71.1of them responsible for some regions, were redistrib-
uted in classical divisions of the national territory
(north, center, south). The distribution of centers
in defined areas compared to the local population
represents a valid sampling for statistical analysis
(48 departments of general surgery, 46 departments
of gynecology, 52 departments of orthopedics).
Our response ratewas 68.2%, and the surveywas
nationwide. This rate is consistent with othermailed
physician surveys, in which the typical response is
approximately50%.7,8Selectionbias is always acon-
cern and may limit the generalizability of the find-
ings, and this may mean that those who did
respond tended to support guidelines and were
more likely to be more knowledgeable. Moreover,
actual compliance with guidelines is probably lower
among nonrespondents, while respondents may
tend to overestimate the extent to which they com-
ply in practice. We examined the impact of nonres-
ponding physicians. The best approach suggested to
understand the role of nonresponse bias is to use var-
iables known for a sufficiently large and representa-
tive sample of nonresponders and to compare them
with those of responders.9 We were able to compare
baseline demographic and practice variables of
Table IV. Availability of diagnostic resources
Kind of device %
Radiography 99.1
CT 95.6
MR 58.1
Phlebography 59.1
Ultrasonography 92.6
Angio-CT 70.5
Angio-MR 45.6
Plethysmography 22.6
Perfusional scintigraphy 46.8
Ventilatory scintigraphy 27.3
Marked fibrinogen vein scintigraphy 25.0
aPTT evaluation 99.1
PT evaluation 100
INR evaluation 98.2
Fibrinogen evaluation 99.1
Factor XII 57.4
D-dimer evaluation 88.3
FDP evaluation 87.3
Protein C evaluation 82.9
Protein S evaluation 70.6
AT III evaluation 95.5
Homocysteine evaluation 57.4
CT, computed tomography; MR, magnetic resonance; aPTT,
activated partial thromboplastin time; PT, partial
thromboplastin; INR, international normalized ratio; FDP,
fibrinogen degradation product; AT III, antithrombin III; Angio
TC, computed tomography angiography; Angio RM, magnetic
resonance angiography.
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that all characteristics of the two groups exhibit the
same pattern with no statistically significant differ-
ences, so we infer that there was no selection bias
in these data and that the findings may be represen-
tative of all populations of physicians.
The evidence proves that the ability to recognize
all major signs and symptoms of suspected DVTePE,
although adequate, suffers from a moderate under-
evaluation of all the early signs and symptoms
which are indicative of the problem.
 ForDVT:pain(89.3%)andedemaof the lower limbs
(76.3%), fever (24.4%), functional limitations of
Table V. Diagnostic data waiting
Kind of device
<12
hr (%)
>12 <48
hr (%)
<48
hr (%)
Radiography 61.6 31.5 6.8
CT 44.0 29.3 26.6
MR 42.0 8.0 50.0
Phlebography 2.6 74.4 23.1
Ultrasonography 52.0 28.1 19.8
Angio-CT 26.8 36.6 35.6
Angio-MR 33.3 8.3 46.7
Plethysmography 40.0 46.7 13.3
Perfusional scintigraphy 11.1 66.7 22.2
Ventilatory scintigraphy 18.2 18.2 63.6
Marked fibrinogen vein
scintigraphy
33.3 50.0 16.7
aPTT evaluation 46.7 25.3 28.1
PT evaluation 46.7 25.3 28.1
INR evaluation 46.7 25.3 28.1
Fibrinogen evaluation 45.9 25.7 24.4
Factor XII 39.0 17.1 43.91
D-dimer evaluation 38.6 29.8 31.6
FDP evaluation 49.2 23.8 27.0
Protein C evaluation 82.9 82.9 82.9
Protein S evaluation 36.4 16.0 47.7
AT III evaluation 47.2 20.8 31.9
Homocysteine evaluation 34.2 15.8 50.0
CT, computed tomography; MR, magnetic resonance; aPTT,
activated partial thromboplastin time; PT, partial
thromboplastin; INR, international normalized ratio; FDP,
fibrinogen degradation product; AT III, antithrombin III; Angio
TC, computed tomography angiography; Angio RM, magnetic
resonance angiography.
Table VI. Annual and triennial mortality for
DVTePE
Mortality DVT PE Total
Cumulative (3 years)(number
of cases /100,000 inhabitants)
1.55 0.65 2.20
Annual(number of cases /
100,000 inhabitants)
0.51 0.21 0.72the lower limbs (20.6%), positive Homans maneu-
vre (19.8%), venous reticula (14.5%).
 For PE: dyspnea (92.5%), thoracic pain (70.1%),
tachypnea (50.7%), cough (27.6%), hemoptysis
(26.8%), anxiety (19.4%), sweating (19.4%).
Data suggest good clinical attention to evidence
that appearsmore suggestiveand,probably, poorat-
tention to the complex patophysiology of the event.
Actually, guidelines are mainly aimed at physi-
cians who do not specialize in this specific area. In-
deed, they seem to be more interested in the legal
Table VII. Kind of prophylaxis
Kind of device %
Early mobilization 39.3
Anticoagulant drugs 93.1
Elastic compression 37.8
Antiplatelet drugs 2.2
Other 8.3
Table VIII. Medical treatment before and after
surgery
Kind of drug %
Before surgery
Antibiotics 83.9
Anti-inflammatories 14.9
Anticoagulants 80.8
Antiplatelets 15.4
After surgery
Antibiotics 76.9
Anti-inflammatories 57.6
Anticoagulants 90.7
Antiplatelets 31.7
Table IX. Echo color Doppler, angio-computed
tomography, and D-dimer: data waiting and area
Clinical centers
Data waiting
<12 hr (%)
Data waiting
>12 hr (%)
Methodology not
available (%)
Echo color Doppler
North 0 % 94.16 % 5.84 %
Center 48.89 % 48.89 % 2.22 %
South 33.33 % 57.58 % 9.09 %
Angio-computed tomography
North 7.35 % 89.71 % 35.29 %
Center 46.67 % 48.89 % 20.00 %
South 21.21 % 69.70 % 39.39 %
D-dimer
North 10.29 % 80.88 % 8.82 %
Center 29.55 % 63.64 % 6.82 %
South 6.06 % 69.70 % 24.24 %
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laboratory strategies, rather than following the
recommendations.
The answers have demonstrated adequate
knowledge of the instrumental and laboratory diag-
nostic pathways, useful to confirm TE (80%). The
evidence of a major interest in a main and more up-
dated methodology (ultrasound, D-dimer, angio-
computed tomography) suggests consistent attention
to the recent literature. Health-care facilities in-
volved in this study refer to an inadequate presence
of instrumental and laboratory resources, necessary
to confirm risk factors for diagnosis in case of sus-
pected disease (80%). The element related to data
waiting represented an unexpected surprise: in the
vast majority of cases, data are not supplied within
12 hr. Basically, TE is a disease which can be treated
thanks to adequate therapeutic systems. DVTePE
therapy is structured on the use of heparin together
with a physical treatment. Pathophysiology of the
thromboembolic disease suggests that a precocious
therapeutic action represents the limit between
the solution of the episode and the evolution to
complications. A diagnostic delay can severely
Table X. Comparison of echo color Doppler, angio-computed tomography, and D-dimer: data waiting
and mortality rate
Data waiting <12 hr Data waiting >12 hr
Mortality DVT PE DVT PE
Echo color Doppler
Cumulative (3 years)(number of cases /100,000
inhabitants)
0.0052 0.0008 0.0013 0.1848
Annual(number of cases /100,000 inhabitants) 0.0018 0.0000 0.0004 0.0615
Angio-computed tomography
Cumulative (3 years)(number of cases /100,000
inhabitants)
0.0114 0.0012 0.0015 0.1445
Annual (number of cases /100,000 inhabitants) 0.0038 0.0004 0.0005 0.0482
D-dimer
Cumulative (3 years) (number of cases /100.000
inhabitants)
0.0049 0.0007 0.0018 0.1654
Annual (number of cases /100.000 inhabitants) 0.0017 0.0002 0.0006 0.0551
0
0,02
0,04
0,06
0,08
0,1
0,12
0,14
0,16
0,18
0,2
data wait < 12
hrs
data wait > 12
hrs
DVT (3 years)
DVT (1 year)
PE (3 years)
PE (1 year)
Fig. 2. Comparison of echo color Doppler data waiting
and mortality rate.
0
0,02
0,04
0,06
0,08
0,1
0,12
0,14
0,16
data wait <
12 hrs 
data wait >
12 hrs 
DVT (3 years)
DVT (1 year)
PE (3 years)
PE (1 year)
Fig. 3. Comparison of angio-computed tomography data
waiting and mortality rate.
0
0,02
0,04
0,06
0,08
0,1
0,12
0,14
0,16
0,18
data wait <
12 hrs
data wait >
12 hrs
TVP (3 years)
TVP (1 year)
EP (3 years)
EP (1 year)
Fig. 4. Comparison of D-dimer data waiting and mortal-
ity rate.
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posed is that when a diagnostic pathway is defined,
it is necessary to think of an ‘‘effective diagnosis,’’
i.e., a useful diagnosis, in the answer and timing in
order to apply the correct therapy. Guidelines, al-
though precise, accurate, and schematic in diagnos-
tic recommendations, never mention adequate
timing for the diagnostic procedures. To confirm
the above-mentioned, data waiting and mortality
in DVTePE were elaborated and compared. It is ev-
ident that an absolute increase of mortality related
to a delay (of more than 12 hr) in the supplying of
data. This delay was the same for DVT and PE but
probably more important for DVT because this led
to PE not being diagnosed and, consequently, to
an apparent increase of mortality for DVT. In this
group of answers concerning mortality, a low mor-
tality rate in DVT was reported. The centers were
asked about mortality data only for patients with
confirmed or post-mortem diagnosis; thus, the de-
clared mortality in PE by all means refers to events
intrinsically mortal.
Mortality in DVT may represent an underesti-
mated element related to the lack of diagnosis of
PE or to a major event different from PE that arose
before its identification. The literature indicates
a known mortality from PE of 13% (8.97/100,000
inhabitants),10 so the data for mortality from DVT,
which might represent a risk factor for TE, should
be investigated. In recent years, different incidence
rates of morbidity and mortality for TE related to
the kind of patient, i.e., those attending general
surgery, gynecology, and orthopedics units, have
emerged in various studies.5,6 Differences seem to
be related to a different sensitivity to the problem
and to varying cultural integration of single
specialities.
In this study, a higher mortality from PE was
found in general surgery departments and a higher
morbidity for DVT and PE in orthopedics and gyne-
cology. It can be supposed that higher morbidity co-
incides with a best identification that coincides with
an adequate treatment and vice versa. The identified
anomalies related to data waiting and mortality
were investigated, creating from the whole data
a partial regional data area (north, center, south).
The most inadequate answers seem to belong to
the northern regions that traditionally are recog-
nized as being equipped with high technology and
structural resources. An explanation could be attrib-
uted to the different health-care regional systems,
expressed by different applications of the Diagnosis-
Related Groups system that might represent, in
Table XI. Morbidity and mortality rates versus clinical centers
Cumulative (3 years) (number of cases/100,000 inhabitants) Annual (number of cases/100,000 inhabitants)
DVT PE DVT PE
Morbidity
General Surgery 0.0280 0.02427 0.0093 0.0810
Orthopedics 0.2057 0.1845 0.0686 0.0615
Gynecology 0.0589 0.0536 0.0196 0.0179
Mortality
General Surgery 0.0034 0.7828 0.0011 0.2609
Orthopedics 0.0020 0.0017 0.0001 0.0001
Gynecology 0.0015 0.0003 0.0005 0.00001
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1
General Surgery Orthopaedics Ginaecology
DVT (3 years)
DVT (1 year)
PE (3 years)
PE (1 year)
Fig. 5. Morbidity rate versus clinical centers.
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1
General Surgery Ortopaedics Gynaecology
DVT (3 years)
DVT (1 year)
PE (3 years)
PE (1 year)
Fig. 6. Mortality data versus clinical centers.
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VTE is a major cause of mortality and morbidity
for Western populations. Its annual incidence over
the general population is 145/100,000 for DVT and
69/100,000 for PE.11-13 Just 13% of PE cases are
fatal (mortality 8.97 cases/100,000 inhabitants1).
Thus, VTE is a major issue in health care and social
cost.14-16 About three-fourths of VTE cases occur
in medical patients, and about one-fourth are found
in surgical patients for whom risk factors represent
a precise condition.
CONCLUSIONS
Surgical procedure and trauma involve a higher
probability of developing a major event. In these
patients, risk stratification and adequate applica-
tion of prophylaxis and treatment devices repre-
sent a real possibility to control morbidity and
mortality. Diagnostic data waiting is a fundamen-
tal factor for adequate prophylaxis, and this study
has clearly shown that in Italy only 40% of cen-
ters today are able to provide diagnostic data
within 12 hr.
Hospital Department Head
Casa di cura S. Rita Ciro’ MarinaeKr General Surgery E. Massari
Ospedale di Palermo General Surgery G. Lombardo
Ospedale di Latina-Formia General Surgery G. Cardi
Ospedale di Matera Orthopedics A. Laforgia
Ospedale di Ragusa Gynecology and Obstetrics S. Iannizzotto
Ospedale di Caltanissetta Orthopedics D. Morgante
ASL n7 Ospedale diRagusa Gynecology and Obstetrics S. D’Asta
Ospedale di Roma General Surgery M. Farao
Osp. S. Francesco Venosa Potenza Orthopedics G. Bruno
Asl n6 Ospedale di Cefalu’- Palermo General Surgery G. Mastrandrea
Ospedale di Rossano General Surgery L. Cloro
Casa di cura Sant’Anna Cagliari Gynecology and Obstetrics F. Angioni
Ospedale Cristo Re Roma General Surgery C. Allegri
Ospedale Santa Maria della Misericordia Sorrento General Surgery De Rosa
Ospedale Monadi di Napoli Orthopedics R. Magri
Ospedale di Salerno Orthopedics S. D’Auria
Ospedale di Cosenza General Surgery A. Petrassi
Ospedale di Potenza Orthopedics S. Accordo
Ospedale di Trapani Gynecology and Obstetrics A. Governale
Villa del Sole Catanzaro General Surgery V. Aloi
Ospedale di Catania Gynecology and Obstetrics S. Caschetto
Ospedale di Castrovillari Orthopedics L. Tarsia
Casa di cura S. Giuseppe, Roma Orthopedics A. Schiavone Panni
Ospedale di Roma General Surgery E. Fedele
Ospedale di SCIACCA Orthopedics A. Vella
Ospedale di Potenza General Surgery L. Luccioni
Ospedale di Napoli Orthopedics L. Grosso
Ospedale di Isernia Gynecology and Obstetrics L. Falasca
Ospedale Civile di Atessa General Surgery A. M. Vitalone
Ospedale di Lanciano, Vasto General Surgery G. Marchese
Ospedale Renzetti, Lanciano General Surgery G. Lesti
Ospedale San Liberatore, Teramo Orthopedics T. De Iure
Ospedale San Salvatore, L’Aquila Gynecology and Obstetrics F. Cappa
Azienda Ospedaliera Senese General Surgery S. Mancini
Ospedale di Piombino (ASL 6), Livorno General Surgery A. Andreini
Azienda Ospedaliera Careggi, Firenze Orthopedics R. Capanna
Azienda Ospedaliera Senese Orthopedics L. Bocchi
Ospedale di Fivizzano (ASL 1), Massa Orthopedics S. Limontini
Ospedale di Massa (ASL 1) Massa Gynecology and obstretics D. Milano
Ospedale di Piombino (ASL 6) Livorno Gynecology and Obstretics N. Calonaci
Ospedale di Empoli (ASL 11) Gynecology and Obstetrics M. Filippeschi
Azienda Ospedaliera Senese Gynecology and Obstetrics F. Petraglia
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